Literature DB >> 31748266

Are Biotransformation Studies of Therapeutic Proteins Needed? Scientific Considerations and Technical Challenges.

Simone Schadt1, Simon Hauri2, Filipe Lopes2, Martin R Edelmann2, Roland F Staack2, Roberto Villaseñor2, Hubert Kettenberger2, Adrian B Roth2, Franz Schuler2, Wolfgang F Richter2, Christoph Funk2.   

Abstract

For therapeutic proteins, the currently established standard development path generally does not foresee biotransformation studies by default because it is well known that the clearance of therapeutic proteins proceeds via degradation to small peptides and individual amino acids. In contrast to small molecules, there is no general need to identify enzymes involved in biotransformation because this information is not relevant for drug-drug interaction assessment and for understanding the clearance of a therapeutic protein. Nevertheless, there are good reasons to embark on biotransformation studies, especially for complex therapeutic proteins. Typical triggers are unexpected rapid clearance, species differences in clearance not following the typical allometric relationship, a mismatch in the pharmacokinetics/pharmacodynamics (PK/PD) relationship, and the need to understand observed differences between the results of multiple bioanalytical methods (e.g., total vs. target-binding competent antibody concentrations). Early on during compound optimization, knowledge on protein biotransformation may help to design more stable drug candidates with favorable in vivo PK properties. Understanding the biotransformation of a therapeutic protein may also support designing and understanding the bioanalytical assay and ultimately the PK/PD assessment. Especially in cases where biotransformation products are pharmacologically active, quantification and assessment of their contribution to the overall pharmacological effect can be important for establishing a PK/PD relationship and extrapolation to humans. With the increasing number of complex therapeutic protein formats, the need for understanding the biotransformation of therapeutic proteins becomes more urgent. This article provides an overview on biotransformation processes, proteases involved, strategic considerations, regulatory guidelines, literature examples for in vitro and in vivo biotransformation, and technical approaches to study protein biotransformation. SIGNIFICANCE STATEMENT: Understanding the biotransformation of complex therapeutic proteins can be crucial for establishing a pharmacokinetic/pharmacodynamic relationship. This article will highlight scientific, strategic, regulatory, and technological features of protein biotransformation.
Copyright © 2019 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31748266     DOI: 10.1124/dmd.119.088997

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  6 in total

1.  N-terminus of Etanercept is Proteolytically Processed by Dipeptidyl Peptidase-4.

Authors:  Sho Masui; Atsushi Yonezawa; Kotoko Yokoyama; Noriko Iwamoto; Takashi Shimada; Akira Onishi; Hideo Onizawa; Takayuki Fujii; Kosaku Murakami; Koichi Murata; Masao Tanaka; Shunsaku Nakagawa; Daiki Hira; Kotaro Itohara; Satoshi Imai; Takayuki Nakagawa; Makoto Hayakari; Shuichi Matsuda; Akio Morinobu; Tomohiro Terada; Kazuo Matsubara
Journal:  Pharm Res       Date:  2022-08-19       Impact factor: 4.580

2.  Bioanalysis in the Age of New Drug Modalities.

Authors:  Jing Shi; Xuesong Chen; Jianbo Diao; Liying Jiang; Lan Li; Stephen Li; Wenzhong Liang; Xiaoying Jin; Yonghui Wang; Colton Wong; Xiaolong Tom Zhang; Francis L S Tse
Journal:  AAPS J       Date:  2021-05-03       Impact factor: 4.009

Review 3.  Immunoaffinity Capillary Electrophoresis in the Era of Proteoforms, Liquid Biopsy and Preventive Medicine: A Potential Impact in the Diagnosis and Monitoring of Disease Progression.

Authors:  Norberto A Guzman; Daniel E Guzman
Journal:  Biomolecules       Date:  2021-10-01

4.  Assessment of Antibody Stability in a Novel Protein-Free Serum Model.

Authors:  Joachim Schuster; Vinay Kamuju; Roman Mathaes
Journal:  Pharmaceutics       Date:  2021-05-22       Impact factor: 6.321

5.  Functional in vitro assessment of modified antibodies: Impact of label on protein properties.

Authors:  Martin R Edelmann; Simon Hauri
Journal:  PLoS One       Date:  2021-09-16       Impact factor: 3.240

6.  Challenges of non-clinical safety testing for biologics: A Report of the 9th BioSafe European Annual General Membership Meeting.

Authors:  Thomas Kissner; Guenter Blaich; Andreas Baumann; Sven Kronenberg; Adam Hey; Andrea Kiessling; Petra M Schmitt; Wouter Driessen; Chantal Carrez; Daniel Kramer; Jennifer Fretland; Wolfgang F Richter; Tobias Paehler; Ulrike Hopfer; Benno Rattel
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.